SMC accepts Kyntheum®▼ (brodalumab) for psoriasis

Hannah Alderton 15 May 2018

The Scottish Medicines Consortium (SMC) has issued advice accepting brodalumab 210mg for restricted use within NHS Scotland. Following a successful resubmission, the SMC has accepted brodalumab for the treatment of moderate-to-severe plaque psoriasis in adult patients who have not responded to standard systemic therapies, or who are unable to take them.

This advice is contingent on the continued provision of a Patient Access Scheme (PAS), under which brodalumab is offered at a confidential discount to the NHS, or a list price that is equivalent or lower. Following this assessment, brodalumab will be available to appropriate patients on the NHS in Scotland.

Nearly 1.8 million people live with psoriasis in the UK and it is estimated that more than 160,000 people live with the condition in Scotland. An estimated 20% of people with psoriasis can develop a moderate or severe form of the disease.

Professor David Burden, Consultant Dermatologist at the University of Glasgow said "This decision from the SMC is significant news for people in Scotland living with psoriasis, an often misunderstood, lifelong and visible condition that can have a huge physical and emotional impact. Brodalumab has a different way of working compared to other biologics currently available and so represents a further expansion of the treatment options available, offering greater choice for our patients."


Make a comment

To voice your opinion, please Log in or Register.

Pf Magazine

Your resource for news, features, interviews, careers and events in the pharma industry.

Click here for the latest issue and to subscribe.